Mealey's (October 11, 2022, 7:26 AM EDT) -- WASHINGTON, D.C. — Although urging the Federal Circuit U.S. Court of Appeals to uphold in full a final written decision (FWD) by the Patent Trial and Appeal Board in one inter partes review (IPR) of its biomolecule identification patent, the patent owner is cross-appealing a separate FWD that deemed various claims of the same invention anticipated and obvious....